Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:

NCT ID: NCT03360981 Recruiting - Clinical trials for Coronary Artery Disease

Epicardial Fat and Clinical Outcomes After Coronary Artery Bypass Grafting in Diabetics vs. Non Diabetics

Start date: September 20, 2017
Phase: Phase 4
Study type: Interventional

Cardiovascular disease (CVD) is a group of diseases including both the heart and blood vessels, thereby including coronary heart disease (CHD). To date, diabetics have a higher incidence and prevalence of multivessels CHD. Treatments in multivessels CHD in diabetics include full medical anti ischemic therapy, and revascularization therapy (Percutaneous coronary intervention (PCI) and/or Coronary artery bypass grafting (CABG)). Randomized trials comparing multivessel PCI to CABG have consistently demonstrated the superiority of CABG in reducing mortality, myocardial infarctions and need for repeat revascularizations. After the CABG treatment, diabetics vs. non-diabetics evidenced a worse prognosis, and an increased mortality. Numerous molecular, epigenetics (as microRNAs), and other metabolic risk factors may condition the worse prognosis in diabetics vs. non diabetics after CABG. In this context, an increased epicardial fat tissue thickness may be independently associated with the prevalence of diabetes, and diabetics have an higher epicardial fat tissue thickness, volumetry, and enhanced metabolism. Therefore, after CABG, lifestyle and medical improvements may lead to the reduction of epicardial fat thickness, extension, and metabolism in both non-diabetics, and diabetics, ameliorating the prognosis. At moment, epicardial tissue function in diabetics is not well investigated in literature, and no data has been reported about new hypoglycemic drugs, and its pleiotropic effects on diabetics after CABG. Indeed, our study hypothesis was that, epicardial fat tissue dimension, and metabolic activity may be related to a different expression of inflammatory, oxidative, and apoptotics molecules, and epigenetic effectors in diabetics vs. non-diabetics. Secondary, these effectors, and epicardial tissue dimension and activity, may be controlled, after CABG, by incretin treatment in diabetics. Therefore, incretin therapy may be associated to the reduction in epicardial fat tissue thickness, and extension, with down regulation of different inflammatory, oxidative and apoptotics molecules, and epigenetic effectors involved in epicardial fat metabolism. Moreover, in this study authors will evaluate in diabetics vs. non diabetics, and in diabetic incretin-users vs. never.-incretin-users, all cause mortality, cardiac mortality, and Major adverse cardiac events (MACE) after CABG in diabetics vs. non diabetics, and diabetic incretin-users (6 months of incretin therapy) vs. diabetic never-incretin-users. Authors will correlate these clinical endpoints to the study of the epicardial fat anatomy and metabolism before and after CABG, and to circulating inflammatory and pro-apoptotic markers, epigenetic effectors, and stem cells in diabetics vs. non diabetics, and diabetic incretin-users (6 months of incretin therapy) vs. diabetic never-incretin-users.

NCT ID: NCT03360591 Recruiting - Clinical trials for Coronary Artery Disease

Functional Assessment In TAVI: FAITAVI

FAITAVI
Start date: November 24, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare the clinical outcome of patients with severe aortic valve stenosis and associated significant coronary artery disease treated with TAVI and a percutaneous myocardial revascularization dictated according to two different strategies: 1. the Angiographically-guided strategy; 2. the Physiologically-guided strategy.

NCT ID: NCT03358680 Recruiting - Clinical trials for Coronary Artery Disease

Temperature and Analgesia Monitoring During Cardial Parmonary Bypass

Start date: April 1, 2017
Phase: N/A
Study type: Observational

In this study, 1. Investigator will apply IOC2 to reflect the depth of analgesic during hypothermia in CPB period. 2. Furthermore, investigator evaluated the effectiveness of IOC2 monitoring for anesthetic depth versus commonly used vital sign monitoring based on factors such as blood pressure and heart rate. 3. Evaluate the other sedation co-relation measurement, include BIS , IOC2 to reflected the consciousness during the operation. 4. Evaluate the other hemodynamic index, include CO, SVV, CVP, PPV to reflect the circulation function , and the effect to the IOC2 and IOC1. 5. Describe the trend of all the measurement. detect the variation of the index during the temperature change during the CPB.

NCT ID: NCT03355742 Not yet recruiting - Clinical trials for Coronary Artery Disease

XIENCE 28 Global Study

Start date: December 27, 2017
Phase: N/A
Study type: Interventional

XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System [EECSS], XIENCE Alpine EECSS, XIENCE PROX EECSS, or XIENCE Sierra EECSS of coronary drug-eluting stents

NCT ID: NCT03354273 Not yet recruiting - Clinical trials for Coronary Artery Disease (CAD)

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Start date: February 2018
Phase: Phase 3
Study type: Interventional

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

NCT ID: NCT03353779 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Impact Of Platelet Function on 1-year Outcome in Complex PCI Patients

Start date: November 30, 2017
Phase: N/A
Study type: Observational

To identify the optimal cut-off values in different platelet function testing to predict MACCE at 12-months in complex PCI patients of China

NCT ID: NCT03351738 Not yet recruiting - Clinical trials for Stable Coronary Heart Disease

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

Start date: December 7, 2017
Phase: Phase 2
Study type: Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

NCT ID: NCT03349385 Recruiting - Clinical trials for Coronary Arteriosclerosis

Registry of Secondary Revascularization

REVASEC
Start date: November 22, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The study will evaluate patients with, at least, one previous procedure of coronary revascularization (surgical, percutaneous or both), that are referred for a new, clinically indicated, diagnostic coronary angiography, to describe their clinical characteristics, management, and prognosis, and will propose a prognosis-oriented classification.

NCT ID: NCT03344653 Recruiting - Clinical trials for Coronary Artery Disease

A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients

Onyx ONE
Start date: November 2, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving reduced duration (1 month) of DAPT following stent implantation.

NCT ID: NCT03340948 Completed - Clinical trials for Coronary Artery Disease

The Mindfulness Intervention as Myocardial Infarction Rehabilitation Additive (MIMIRA) Study

MIMIRA
Start date: January 31, 2012
Phase: N/A
Study type: Interventional

The Mindfulness Intervention as Myocardial Infarction Rehabilitation Additive (MIMIRA) study aimed at studying the feasibility and acceptability of Mindfulness Based Stress Reduction - an 8 week course in meditation and yoga - in patients with a recent coronary artery event and elevated depressive symptoms. To address these questions patients with elevated scores on a depression scale were invited to participate in MBSR, and there evaluation of the course as well as a panel of psychological risk factors and resources was measured.